Comparative Pharmacology
Head-to-head clinical analysis: LEVO T versus RECORLEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVO T versus RECORLEV.
LEVO-T vs RECORLEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic form of thyroxine (T4), a thyroid hormone. It is deiodinated to triiodothyronine (T3), which binds to nuclear thyroid hormone receptors, resulting in modulation of gene transcription and increased metabolic rate.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
1.6 mcg/kg orally once daily (typical adult starting dose 50-100 mcg/day); adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH.
150 mg orally twice daily with a high-fat meal.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days in euthyroid individuals; in hyperthyroidism, half-life shortens to 3-4 days; in hypothyroidism, it prolongs to 9-10 days. The long half-life supports once-daily dosing.
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
Renal: ~20-40% of administered levothyroxine is excreted in urine as unchanged drug and conjugates; biliary/fecal: ~40-60% is excreted in feces via bile, largely as conjugates and minor amounts of unchanged drug.
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Category C
Category C
Thyroid Hormone
Thyroid Hormone